Lipopolysaccharide-mediated protection against Klebsiella pneumoniae-induced lobar pneumonia: intranasal vs. intramuscular route of immunization.
Immunoprotective potential of delivered lipopolysaccharide (LPS) preparation from Klebsiella pneumoniae was determined in a murine model of lobar pneumonia. Protection was assessed with three doses of LPS (25, 50 and 100 microg; without any adjuvant) administered intranasally or intramuscularly. After evaluation of lung tissue (bacterial load and histopathology), no significant protection was observed at 25 microg with either application. A significant decrease in lung bacterial load coupled with fall in severity of lung lesions was observed with 50 microg (again both applications). At 100 microg dose, with intramuscular route, a further decrease in the lung bacterial load was shown compared to the 50 microg dose. In contrast, 100 microg LPS, when given intranasally, resulted in a higher bacterial colonization of the lung tissue and higher lung pathology; thus we recommend intramuscular instead of the intranasal route for developing protection against K. pneumoniae-mediated pneumonia with intact LPS-based vaccines.
Yadav
V
V
Department of Microbiology, Panjab University, Chandigarh 160014, India.
Sharma
S
S
Harjai
K
K
Mohan
H
H
Chhibber
S
S
D000281:Administration, Intranasal; D000818:Animals; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D007114:Immunization; D007194:India; D007273:Injections, Intramuscular; D007710:Klebsiella Infections / Q000382:microbiology / Q000517:prevention & control*; D007711:Klebsiella pneumoniae / Q000254:growth & development / Q000276:immunology*; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D008168:Lung / Q000382:microbiology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D018410:Pneumonia, Bacterial / Q000382:microbiology / Q000517:prevention & control*
D008070:Lipopolysaccharides